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Abstract
Flaws in research papers are common but it may require arduous detective work to unravel them.
Checklists are helpful, but many inconsistencies will only be revealed through repeated cross-
checks of every little detail, just like in a crime case. As a major deterrent for dishonesty, raw data
from all trials should be posted on a public website. This would also make it much easier to detect
errors and flaws in publications, and it would allow many research projects to be performed
without collecting new data. The prevailing culture of secrecy and ownership to data is not in the
best interests of patients.
Background
We build on the scientific results of others when we
choose treatments and plan new research. It is a challenge,
however, how to do this most effectively and reliably, as
flaws in research are common.
Most users of the scientific literature read vastly more con-
clusions than they read abstracts, and vastly more
abstracts than full papers. This approach is difficult to
avoid, but it is a high-risk strategy. Although our intention
might be to use conclusions and abstracts only as screen-
ing tests, helping us to identify those papers that merit a
closer look, it is impossible to actively suppress what we
have just "learnt" from a cursory reading. The human
brain doesn't work that way, in fact, it is remarkably good
at memorizing things we have been exposed to in a flash.
Conclusions are the worst part of papers, and they are
often tainted by wishful thinking, academic ambition, or
the influence of money. Commercial pressures may
explain, for example, why conclusions in randomised tri-
als recommended the experimental drug as the drug of
choice much more often if the trial was funded by for-
profit organisations, even after adjustment for the effect
size (odds ratio 5.3) [1].
Abstracts may not be any better. A review of 520 randomly
selected abstracts found that the first result in the abstract
was statistically significant in 70% of the trials, 84% of
cohort studies, and 84% of case-control studies [2].
Although many of these results were derived from sub-
group or secondary analyses, or biased selection of results,
they were presented without reservations in 98% of the
trials. As true progress in therapeutics or in scientific
knowledge is relatively rare, these results indicate that sig-
nificant P-values in abstracts should generally be disbe-
lieved.
Because of the many problems in research papers, the task
of reviewing research critically is important and has devel-
oped into a science of its own. But it took time to gain
momentum. Gene Glass coined the term meta-analysis in
1976 [3], but even as late as in 1990, one would find only
about 150 meta-analyses on MEDLINE. Most of the essen-
tial knowledge we now have about bias in research papers
comes from methodological studies published within the
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last 15 years. This knowledge has mainly been derived
from empirical studies of randomised trials but it is also
useful when evaluating results of observational research.
The methodological studies have made it clear that a
failed study can be so nicely dressed up that most readers
would think the study is reliable, somewhat like a lit de
parade where one might think that the deceased, lying
peacefully in his or her best clothes, is not dead, but only
sleeping.
The deeper one digs, the more one finds. Authors of sys-
tematic reviews and other critical readers of scientific
papers may therefore wish to take on the role as research
detective, which has similarities to the work of a police
detective. First of all, no matter how respected the authors,
their institution and the journal, the starting point should
be that important evidence might have been covered up,
and that people could be lying. We once asked 102 trial-
ists whether they had measured outcomes they had not
reported. Only 48% responded, and 86% of the remain-
ing authors initially denied the existence of unreported
outcomes, prior to receiving our list of unreported out-
comes that we had compiled from the trial protocols [4].
We do not interpret this as lying but rather as an example
that people tend to reply to questionnaires in a way that
shows themselves in a favourable light, in particular when
they think it would not be possible to check their replies.
Second, it is hard to find out what is not there, but which
should have been there, whether it is a nicely cleaned
research paper or a nicely cleaned crime site. Checklists
are helpful, but mostly for inexperienced detectives. Quite
often, something is wrong that will not be captured by a
checklist, but which is more likely to be revealed the more
experience the detective has, the more time he devotes to
the case, and the more pedantic he is, checking every little
detail again and again, also against other details, as there
is an important learning process that necessitates going
back to issues one has already dealt with.
Discussion
The case study recently published in Trials by Karim Hirji
[5] is an example that many important problems can
sometimes be found with a trial if one is persistent. What
makes the case particularly interesting are that most of the
problems would not have been captured by a checklist,
and that both participants at a course on evidence-based
medicine (who are usually very good at spotting problems
together) and authors of systematic reviews consistently
considered the trial to be of high quality, although it
might have been fatally flawed in several respects.
Several of the flaws were well hidden and Hirji used three
months on his investigations, which would not be practi-
cable or cost-effective if this were to be the norm. But we
can still do a good job if we share the workload by co-
operating, like researchers do in The Cochrane Collabora-
tion, where the general idea is that there should be only
one systematic review on a particular issue, which gets
updated if readers alert the authors to important problems
they have missed.
We may hope that Hirji's case was atypical, but I doubt it.
Many of the issues Hirji uncovered are common in trial
reports, e.g. lack of information on exactly which data
were missing when, non-adherence to the trial protocol,
erroneous coding of events, misleading statistical analyses
and a general lack of understanding of basic statistical
principles. A thesis based on a systematic review of 196
head-to-head trials of non-steroidal, anti-inflammatory
drugs revealed an overwhelming amount of bias, much of
which was covert and only detected because results of
meta-analyses agreed poorly with what was claimed in the
individual trial reports [6].
Trials contributes to correcting the scientific record by wel-
coming submissions that discuss trials published else-
where. This is important, as it is usually impossible to get
relevant criticism accepted in the journal that published
the trial after the time limit for publishing letters has
passed, which it does in only two weeks for some journals,
although oversees subscribers may still not have received
the journal. It is difficult to see any good rationale for time
limits for comments that demonstrate fatal flaws. Indeed,
it is similar to dismissing a police detective's proof of the
identity of the killer because a judge or a jury had opined
that the killer was not-guilty, based on existing evidence.
Scientific cases should have no closure date.
Important progress has been made recently towards
greater transparency and less bias in trials. Many journals
refer to the CONSORT statement in their instructions to
authors that aim at improving clarity in reporting [7], the
BMJ [8] and a few other journals now require trial proto-
cols for submission of trial reports, JAMA will not publish
an industry-sponsored trial unless the data analysis was
conducted by an independent statistician at an academic
institution [9], and several journals will not publish a trial
unless it was registered at inception [10]. Furthermore,
work is ongoing aiming at ensuring free access to trial pro-
tocols and to all results from all trials.
Conclusion
I agree with Hirji's suggestion that raw data from all trials
should be posted on a public website. This would be a
major deterrent for flawed analyses and reports, and it
would be much easier to detect errors and flaws in publi-
cations. It would also be tremendously cost-effective, as
many relevant research projects could be performed byPublish with BioMed Central    and   every 
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using data that have already been collected for another
purpose. It is time to change the prevailing culture of
secrecy and ownership to data, as this is clearly not in the
best interests of the patients.
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